Several new pathways and key molecules have been identified, including GR, GATA2, IGF2, ONECUT2, POM121, AURKA, N-Myc, HP1α, PEG10, SRRM4, BRN2, SOX2, and PRMT5, which could be effective therapeutic targets for PCa.365,557–566. The gene discussed is POM121; the disease is posterior cortical atrophy.